Overview
Reunion Neuroscience is developing RE104, a novel psychedelic compound with a shorter duration of action than psilocybin, targeting postpartum depression and major depressive disorder. Their approach aims to improve practicality of psychedelic-assisted therapy.
More in Mental Health Tech
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
💙 Mental Health Tech
Location
Montreal, Canada
Funding
Public · NASDAQ: REUN
Website
reunionneuroscience.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →